AI Portfolio Summary
In 2025 Q4, ARCH Venture Management, LLC maintained a portfolio of 10 distinct positions. The most significant new addition to the portfolio was 10X GENOMICS INC., which now represents 1.85% of the total fund value. Conversely, ARCH Venture Management, LLC completely exited their position in CERO THERAPEUTICS HO.
Total Positions
10
Quarter
2025 Q4
Top Holding
MAZE (26.2%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-10 of 10
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 26.19% | 21.70% |
#1
2
Prev: #3
|
7.0 | no change | no change |
P
S
|
4,120,053 | $170,693,796 |
$11.01
+261.2%
|
2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
BEAM
BEAM THERAPEUTI...
|
Healthcare | 19.31% | 22.38% |
#2
Prev: #2
|
6.5 | no change | no change |
P
S
|
4,540,132 | $125,852,459 |
$23.43
+15.8%
|
2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
RAPP
RAPPORT THERAPE...
|
Healthcare | 17.36% | 22.49% |
#3
2
Prev: #1
|
6.0 | no change | no change |
P
S
|
3,728,738 | $113,129,911 |
$23.26
+20.9%
|
2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
LYEL
LYELL IMMUNOPHA...
|
Healthcare | 13.03% | 9.10% |
#4
1
Prev: #5
|
5.5 | no change | no change |
P
S
|
2,759,072 | $84,924,236 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VIR
VIR BIOTECHNOLO...
|
Healthcare | 11.95% | 14.98% |
#5
1
Prev: #4
|
5.5 | no change | no change |
P
S
|
12,916,663 | $77,887,478 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ERAS
ERASCA INC.
|
Healthcare | 6.31% | 4.89% |
#6
Prev: #6
|
3.5 | no change | no change |
P
S
|
11,055,554 | $41,126,661 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GOSS
GOSSAMER BIO IN...
|
Healthcare | 3.83% | 4.30% |
#7
Prev: #7
|
2.5 | no change | no change |
P
S
|
8,055,916 | $24,973,340 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TXG
10X GENOMICS IN...
|
Healthcare | 1.85% | — |
#8
Prev: #—
|
4.2 | 737,539 | no change |
NEW
|
737,539 | $12,029,261 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
QTTB
Q32 BIO INC.
|
Healthcare | 0.16% | 0.13% |
#9
1
Prev: #8
|
1.1 | no change | no change |
P
S
|
320,482 | $1,064,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CERO
CERO THERAPEUTI...
|
Healthcare | 0.00% | 0.02% |
Sold All 😨
(Was: #9) |
0.0 | -22,389 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-10 of 10 holdings